Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Intangibles: 2018-2025

  • China SXT Pharmaceuticals' Intangibles fell 38.18% to $11,808 in Q1 2025 from the same period last year, while for Mar 2025 it was $11,808, marking a year-over-year decrease of 38.18%. This contributed to the annual value of $11,808 for FY2025, which is 38.18% down from last year.
  • As of Q1 2025, China SXT Pharmaceuticals' Intangibles stood at $11,808, which was down 38.18% from $19,101 recorded in Q1 2024.
  • In the past 5 years, China SXT Pharmaceuticals' Intangibles ranged from a high of $85,728 in Q1 2022 and a low of $11,808 during Q1 2025.
  • In the last 3 years, China SXT Pharmaceuticals' Intangibles had a median value of $19,101 in 2024 and averaged $19,592.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Intangibles increased by 8.08% in 2021, and later tumbled by 67.49% in 2023.
  • Quarterly analysis of 5 years shows China SXT Pharmaceuticals' Intangibles stood at $82,948 in 2021, then rose by 3.35% to $76,398 in 2022, then crashed by 67.49% to $27,868 in 2023, then crashed by 31.46% to $19,101 in 2024, then crashed by 38.18% to $11,808 in 2025.
  • Its last three reported values are $11,808 in Q1 2025, $19,101 for Q1 2024, and $27,868 during Q1 2023.